📰 BloombergBloombergCodex · 实盘不做把握 4/10
北京时间·🕒 发布 08-03 19:24:45时区推断·⟳ 抓取 08-03 19:39:41·⚡ 决策 08-04 09:57:39 +14h17m·84.4 天前
Blue Owl支持的Latigo拟IPO募资最高2.88亿美元
Latigo拟发行1600万股、价格区间16至18美元，最高募资2.88亿美元，顶格估值约11亿美元。
📄 原文Bloomberg↗ 原文
Latigo Biotherapeutics Inc. is seeking to raise as much as $288 million in an initial public offering, joining a growin…
不做 Blue Owl Capital（OWL.US）
Latigo尚未上市且对Blue Owl持股收益未量化；OWL当日已大涨但缺少可归因公司级增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- Bloomberg报道Blue Owl支持的Latigo拟以16至18美元发行1600万股，最高募资2.88亿美元。市场反应:OWL.US 8月3日收涨8.35%，但无法归因于Latigo IPO。
关键理由
- Latigo拟发行1600万股、价格区间16至18美元，最高募资2.88亿美元，顶格估值约11亿美元。
- 该事件主要发生在Blue Owl投资组合公司Latigo，Latigo尚未上市交易，预期代码LTGO尚不可当前交易。
- 对Blue Owl（OWL.US）只是单个组合项目IPO进展，未披露Blue Owl持股比例、账面增值或可分配收益。
主要风险
- OWL.US 8月3日已涨8.35%，但该涨幅不能归因于Latigo IPO；若无持股经济权益量化，不应追多。
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,324 字
Latigo Biotherapeutics Inc. is seeking to raise as much as $288 million in an initial public offering, joining a growing list of biotechnology firms considering going public as soon as this quarter.
The Blue Owl Capital Inc.-backed clinical-stage developer of non-opioid pain medicines is offering 16 million shares for $16 to $18 each, according to its filing Monday with the US Securities and Exchange Commission.
At the top of the price range, the company would have a market value of roughly $1.1 billion, based on the outstanding shares in its filing.
Latigo’s lead drug candidate has shown a roughly 50% greater analgesic effect than Vicodin, a comparable opioid, in a clinical trial, the filing shows. It plans to run a Phase 3 trial for moderate-to-severe acute pain this year and expects to release the results in the second half of next year.
The company joins a handful of biotechs that have filed for US IPOs in recent weeks to take advantage of much improved funding conditions for the sector after a four-year downturn. Listings of biotech and pharmaceutical companies have raised $5.4 billion on US exchanges this year, versus $969.2 million in the corresponding period in 2025, data compiled by Bloomberg show.
Read More: Biotech IPO Gains Crush AI Listings With Standout 55% Return
In March last year Latigo raised $150 million from a Series B financing led by Blue Owl, the filing shows. Latigo’s investors also include Westlake BioPartners, Foresite Capital and 5AM Ventures.
Latigo has raised about $321.5 million since it was founded in 2018 and carried $54.8 million of cash and equivalents at the end of June, according to the filing.
The company had a net loss of $23 million for the three months ended March 31, versus a net loss of $21 million for the corresponding period a year before, the filing shows.
Latigo’s offering is being led by Goldman Sachs Group Inc., Jefferies Financial Group Inc., Leerink Partners and Guggenheim Securities. The company expects its shares to trade on the Nasdaq Global Select Market under the symbol LTGO.
For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS. To subscribe to ECM Watch, Bloomberg’s daily roundup of news from around the region, click here.
The Blue Owl Capital Inc.-backed clinical-stage developer of non-opioid pain medicines is offering 16 million shares for $16 to $18 each, according to its filing Monday with the US Securities and Exchange Commission.
At the top of the price range, the company would have a market value of roughly $1.1 billion, based on the outstanding shares in its filing.
Latigo’s lead drug candidate has shown a roughly 50% greater analgesic effect than Vicodin, a comparable opioid, in a clinical trial, the filing shows. It plans to run a Phase 3 trial for moderate-to-severe acute pain this year and expects to release the results in the second half of next year.
The company joins a handful of biotechs that have filed for US IPOs in recent weeks to take advantage of much improved funding conditions for the sector after a four-year downturn. Listings of biotech and pharmaceutical companies have raised $5.4 billion on US exchanges this year, versus $969.2 million in the corresponding period in 2025, data compiled by Bloomberg show.
Read More: Biotech IPO Gains Crush AI Listings With Standout 55% Return
In March last year Latigo raised $150 million from a Series B financing led by Blue Owl, the filing shows. Latigo’s investors also include Westlake BioPartners, Foresite Capital and 5AM Ventures.
Latigo has raised about $321.5 million since it was founded in 2018 and carried $54.8 million of cash and equivalents at the end of June, according to the filing.
The company had a net loss of $23 million for the three months ended March 31, versus a net loss of $21 million for the corresponding period a year before, the filing shows.
Latigo’s offering is being led by Goldman Sachs Group Inc., Jefferies Financial Group Inc., Leerink Partners and Guggenheim Securities. The company expects its shares to trade on the Nasdaq Global Select Market under the symbol LTGO.
For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS. To subscribe to ECM Watch, Bloomberg’s daily roundup of news from around the region, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。